{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T06:38:14Z","timestamp":1792219094311,"version":"4.4.0"},"reference-count":65,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2012,4,28]],"date-time":"2012-04-28T00:00:00Z","timestamp":1335571200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Acad Dermatol Venereol"],"published-print":{"date-parts":[[2013,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Mutations in genes encoding for proteins along the RAS\u2010RAF\u2010MEK\u2010ERK pathway have been detected in a variety of tumor entities, including malignant melanoma, thyroid, colonic and ovarian carcinomas, and some sarcomas. Thus, a number of inhibitors of this pathway have been developed, whose antitumor potential is currently being assessed in different clinical trials. Up to now one drug of this category (vemurafenib) has been approved by the FDA and the European Commission for late\u2010stage melanoma. Although these new targeted anticancer therapies are generally considered to be safe and well tolerated, certain toxicities have been attributed to them, with cutaneous side effects being perhaps the most frequent amongst them. Based on results of clinical trials and on case series, a distinct profile of cutaneous toxicity has been observed, which is similar to that of EGFR and multikinase inhibitors. As exanthema, palmar\u2010plantar erythrodysesthesia syndrome, hyperkeratosis, xerosis, pruritus, photosensitivity, and paronychia, can be controlled in most cases with common conservative modalities, special attention should be given to the early detection of epithelial skin tumors (mainly keratoakanthomas) that can be induced during therapy with these agents. This report reviews all current published data on cutaneous side effects of RAS\u2010RAF\u2010MEK\u2010ERK pathway inhibitors, and attempts to provide the clinician with clear hints for their management.<\/jats:p>","DOI":"10.1111\/j.1468-3083.2012.04546.x","type":"journal-article","created":{"date-parts":[[2012,4,28]],"date-time":"2012-04-28T06:58:50Z","timestamp":1335596330000},"page":"11-18","source":"Crossref","is-referenced-by-count":83,"title":["Cutaneous side effects of inhibitors of the RAS\/RAF\/MEK\/ERK signalling pathway and their management"],"prefix":"10.1111","volume":"27","author":[{"given":"I.","family":"Manousaridis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Mavridou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Goerdt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Leverkus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Utikal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2012,4,28]]},"reference":[{"key":"e_1_2_5_2_2","doi-asserted-by":"publisher","DOI":"10.1038\/nature00766"},{"key":"e_1_2_5_3_2","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/95.8.625"},{"key":"e_1_2_5_4_2","first-page":"1454","article-title":"High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET\/PTC\u2010RASBRAF signaling pathway in papillary thyroid carcinoma","volume":"63","author":"Kimura ET","year":"2003","journal-title":"Cancer"},{"key":"e_1_2_5_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.molonc.2007.12.003"},{"key":"e_1_2_5_6_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1207785"},{"key":"e_1_2_5_7_2","first-page":"120","article-title":"Sorafenib in advanced melanoma: a Phase\u2010II randomised discontinuation trial analysis","volume":"5","author":"Eisen T","year":"2006","journal-title":"Br J Cancer"},{"key":"e_1_2_5_8_2","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-04-1443"},{"key":"e_1_2_5_9_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6606030"},{"key":"e_1_2_5_10_2","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2009.27.15_suppl.3513","article-title":"A phase\u2010I study of XL281, a selective oral RAF kinase inhibitor, in patients with advanced solid tumors","volume":"27","author":"Schwartz GK","year":"2009","journal-title":"J Clin Oncol"},{"key":"e_1_2_5_11_2","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2010.28.15_suppl.8511","article-title":"Final results of E2603: a double blind, randomized phase\u2010III trial comparing carboplatin\/paclitaxel with or without sorafenib in metastatic melanoma","volume":"28","author":"Flaherty KT","year":"2010","journal-title":"J Clin Oncol"},{"key":"e_1_2_5_12_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1002011"},{"key":"e_1_2_5_13_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1103782"},{"key":"e_1_2_5_14_2","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2010.28.15_suppl.8503"},{"key":"e_1_2_5_15_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2004.01.185"},{"key":"e_1_2_5_16_2","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2011.29.15_suppl.8509","article-title":"BRIM\u20102: an open\u2010label, multicenter phase II study of vemurafenib in previously treated patients with BRAF V600E mutation\u2010positive metastatic melanoma","volume":"29","author":"Ribas A","year":"2011","journal-title":"J Clin Oncol"},{"key":"e_1_2_5_17_2","first-page":"990","article-title":"BREAK\u20102: a phase IIA trial of the selective BRAF kinase inhibitor GSK2118436 in patients with BRAF mutation\u2010positive (V600E\/K) metastatic melanoma","volume":"24","author":"Trefzer U","year":"2011","journal-title":"Pigment Cell Res"},{"key":"e_1_2_5_18_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.14.415"},{"key":"e_1_2_5_19_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.14.4956"},{"key":"e_1_2_5_20_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-09-2483"},{"key":"e_1_2_5_21_2","doi-asserted-by":"publisher","DOI":"10.3109\/02841860903104152"},{"key":"e_1_2_5_22_2","first-page":"990","article-title":"A phase II study of the MEK1\/MEK2 inhibitor GSK1120212 in metastatic BRAF\u2010V600E or K mutant cutaneous melanoma patients previously treated with or without a BRAF inhibitor","volume":"24","author":"Kim KB","year":"2011","journal-title":"Pigment Cell Res"},{"key":"e_1_2_5_23_2","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2011.29.18_suppl.cra8503"},{"key":"e_1_2_5_24_2","first-page":"990","article-title":"Phase I\/II expansion cohort of BRAF inhibitor GSK2118436\u2003+\u2003 MEK inhibitor GSK1120212 in patients with BRAF mutant metastatic melanoma who progressed on a prior BRAF inhibitor","volume":"24","author":"Flaherty K","year":"2011","journal-title":"Pigment Cell Res"},{"key":"e_1_2_5_25_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1610-0387.2010.07561_suppl.x"},{"key":"e_1_2_5_26_2","first-page":"149","article-title":"Dermatologic toxicities of targeted anticancer therapies","volume":"8","author":"Balagula Y","year":"2010","journal-title":"J Support Oncol"},{"key":"e_1_2_5_27_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2009.06.070"},{"key":"e_1_2_5_28_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2010.04.028"},{"key":"e_1_2_5_29_2","doi-asserted-by":"publisher","DOI":"10.4161\/cc.6.23.4998"},{"key":"e_1_2_5_30_2","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2011.108"},{"key":"e_1_2_5_31_2","doi-asserted-by":"publisher","DOI":"10.1038\/nrm2438"},{"key":"e_1_2_5_32_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0507399103"},{"key":"e_1_2_5_33_2","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2011.29.15_suppl.8518","article-title":"Induction of apoptosis by the BRAFV600E kinase inhibitor PLX4032 in BRAFV600E melanoma cells through regulation of endoplasmic reticulum stress\u2010related genes","volume":"29","author":"Meier FE","year":"2011","journal-title":"J Clin Oncol"},{"key":"e_1_2_5_34_2","doi-asserted-by":"publisher","DOI":"10.1091\/mbc.E06-02-0102"},{"key":"e_1_2_5_35_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.molimm.2009.08.010"},{"key":"e_1_2_5_36_2","first-page":"479","volume-title":"Nutritional Diseases. In ANDREWS\u2019 Diseases of the skin","author":"James WD","year":"2006"},{"key":"e_1_2_5_37_2","doi-asserted-by":"publisher","DOI":"10.1097\/CCO.0b013e3283436e8c"},{"key":"e_1_2_5_38_2","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2011.29.15_suppl.8520","article-title":"Presence of frequent underlying RAS mutations in cutaneous squamous cell carcinomas and keratoacanthomas (cuSCC\/KA) that develop in patients during vemurafenib therapy","volume":"29","author":"Lacouture M","year":"2011","journal-title":"J Clin Oncol"},{"key":"e_1_2_5_39_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1105358"},{"key":"e_1_2_5_40_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.36.7680"},{"key":"e_1_2_5_41_2","doi-asserted-by":"crossref","first-page":"53","DOI":"10.4137\/CMO.S5855","article-title":"Novel treatments for metastatic cutaneous melanoma and the management of emergent toxicities","volume":"6","author":"Lemech C","year":"2012","journal-title":"Clin Med Insights Oncol"},{"key":"e_1_2_5_42_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00105-010-2042-4"},{"key":"e_1_2_5_43_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10637-010-9567-3"},{"key":"e_1_2_5_44_2","doi-asserted-by":"publisher","DOI":"10.1159\/000317132"},{"key":"e_1_2_5_45_2","unstructured":"U. S. Department of Health and Human Services National Institutes of Health National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE) version 4.0.http:\/\/evs.nci.nih.gov\/ftp1\/CTCAE\/CTCAE_4.02_2009\u201009\u201015_QuickReference_5x7.pdf(last accessed: 22 May 2010)."},{"key":"e_1_2_5_46_2","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.12-5-610"},{"issue":"5","key":"e_1_2_5_47_2","first-page":"17","article-title":"Clinical management of EGFRI dermatologic toxicities: US perspective","volume":"21","author":"Lacouture M","year":"2007","journal-title":"Oncology"},{"key":"e_1_2_5_48_2","first-page":"1","article-title":"Cutaneous reactions to anticancer agents targeting the epidermal growth factor receptor: a dermatology\u2010oncology perspective","volume":"12","author":"Lacouture M","year":"2007","journal-title":"Skin Therapy Lett"},{"key":"e_1_2_5_49_2","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.10-5-345"},{"key":"e_1_2_5_50_2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdi279"},{"key":"e_1_2_5_51_2","doi-asserted-by":"publisher","DOI":"10.3747\/co.v16i1.361"},{"key":"e_1_2_5_52_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00105-006-1256-y"},{"key":"e_1_2_5_53_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2006.09.005"},{"key":"e_1_2_5_54_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2006.11.016"},{"key":"e_1_2_5_55_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.12.6987"},{"key":"e_1_2_5_56_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.21.7828"},{"key":"e_1_2_5_57_2","article-title":"CYTAR: a randomized clinical trial evaluating the preventive effect of doxycycline on erlotinib\u2010induced folliculitis in non\u2010small cell lung cancer patients","volume":"28","author":"Deplangue G","year":"2008","journal-title":"J Clin Oncol"},{"key":"e_1_2_5_58_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.23621"},{"key":"e_1_2_5_59_2","doi-asserted-by":"publisher","DOI":"10.1038\/nature08996"},{"key":"e_1_2_5_60_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.clindermatol.2009.04.001"},{"key":"e_1_2_5_61_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa060655"},{"key":"e_1_2_5_62_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa065044"},{"key":"e_1_2_5_63_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.23.4823"},{"key":"e_1_2_5_64_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(05)70243-6"},{"key":"e_1_2_5_65_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2005.07010.x"},{"key":"e_1_2_5_66_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.det.2007.08.010"}],"container-title":["Journal of the European Academy of Dermatology and Venereology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1468-3083.2012.04546.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1468-3083.2012.04546.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,15]],"date-time":"2023-10-15T06:48:36Z","timestamp":1697352516000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1468-3083.2012.04546.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,4,28]]},"references-count":65,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2013,1]]}},"alternative-id":["10.1111\/j.1468-3083.2012.04546.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1468-3083.2012.04546.x","archive":["Portico"],"relation":{},"ISSN":["0926-9959","1468-3083"],"issn-type":[{"value":"0926-9959","type":"print"},{"value":"1468-3083","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,4,28]]}}}